Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04017728
Other study ID # 960HP20190051
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 30, 2019
Est. completion date December 2025

Study information

Verified date July 2019
Source Jinan Military General Hospital
Contact Min Li, M.D.
Phone 13953176057
Email liminyingxiang@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Percutaneous vertebroplasty has been applied widely to treat bone metastases. The injected cement may strengthen the affected bone to prevent pathological fractures and relieve the pain. Moreover, the thermal reaction (70°C) due to polymerisation of cement also contributes to tumour destruction. The cement dose and diffusion pattern may be significant factors for the treatment efficacy, which can be affected by the inner pressure of the metastases. The investigators will apply a rotary cutter to destroy the structure of metastases to alleviate the pressure in the metastases. Then, more cement will be injected, which may effectively interdigitates with the surrounding bone and generate more thermo to kill the tumor cells.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date December 2025
Est. primary completion date April 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

1. Imaging-proven and pathology-proven metastases

2. Intractable pain with neurologic dysfunction

Exclusion Criteria:

1. Poor general condition without tolerance of surgery

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Conventional Percutaneous Vertebroplasty
The cement is injected into the bone metastases directly.
Percutaneous Vertebroplasty with Rotary Cutter
The rotary cutter is applied before the cement injection. Then, the cement is injected with lower pressure.

Locations

Country Name City State
China 960 Hospital of PLA Jinan Shandong

Sponsors (1)

Lead Sponsor Collaborator
Li Min

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Back pain: Visual analogue scales system Measuring and comparing the pre- and post-operative back pain via Visual analogue scales (VAS) system with values from 0 to 10 (0 indicating no pain and 10 indicating the worst pain). Patients with a VAS score lower than 3 were classified as the effective group. 3 months
Secondary The patterns of cement opacification The patterns of cement opacification were classified as solid patterns (cement forms a mass), trabecular patterns (cement spread along the fine bone trabeculae), and mixed patterns (cement forms a mass with spreading along the fine bone trabeculae). during the procedure of vertebroplasty
Secondary Cement leakage The presence or absence of cement leakage is assessed in the groups with and without rotary cutter. during the procedure of vertebroplasty
Secondary Cement volume The injected cement volume were evaluated in the two groups. during the procedure of vertebroplasty
See also
  Status Clinical Trial Phase
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Terminated NCT03257722 - Pembrolizumab + Idelalisib for Lung Cancer Study Phase 1/Phase 2
Recruiting NCT01201096 - Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE) N/A
Completed NCT01199822 - Study of the Safety and Pharmacokinetics of IMC-3G3 in Japanese Patients With Solid Tumors Phase 1
Completed NCT01206530 - FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer Phase 1/Phase 2
Completed NCT00313859 - Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC Phase 2
Completed NCT00377936 - EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Phase 2
Recruiting NCT05095207 - Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer Phase 1/Phase 2
Active, not recruiting NCT04392479 - TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study. Phase 3
Recruiting NCT04808466 - Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Phase 2
Terminated NCT03652493 - Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway Phase 2
Not yet recruiting NCT04845490 - Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Phase 2
Recruiting NCT05061082 - Genomic Evolution of Metastasis in Gastric Cancer
Not yet recruiting NCT06055764 - Role of FDG PET/CT in Patients With Metastasis of Unknown Origin
Terminated NCT02796729 - CEST- Glucose Enhanced MRI for Metastatic Brain Tumours Phase 2
Withdrawn NCT01157039 - A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin Phase 2
Terminated NCT01000948 - A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer Phase 2
Terminated NCT01613482 - TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention Phase 3
Withdrawn NCT00244348 - Hepatic Artery Infusion With Oxaliplatin Phase 1/Phase 2
Recruiting NCT04416165 - Comparison of FDG and FAPI in Patients With Various Types of Cancer N/A